Study of Ambrisentan in Subjects With Pulmonary Hypertension (ABS-LT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00777920|
Recruitment Status : Completed
First Posted : October 22, 2008
Last Update Posted : December 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Hypertension||Drug: Ambrisentan||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||140 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension|
|Actual Study Start Date :||November 17, 2008|
|Actual Primary Completion Date :||September 11, 2019|
|Actual Study Completion Date :||September 11, 2019|
Participants will receive ambrisentan 5 mg or 10 mg once daily.
Ambrisentan tablet administered orally once daily
Other Name: Letairis
- Incidence and severity of adverse events (AEs) associated with long-term exposure to ambrisentan in participants with pulmonary hypertension [ Time Frame: Up to 9 years ]Incidence and severity of AEs will be summarized.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00777920
|Study Director:||Gilead Study Director||Gilead Sciences|